Novartis AG $NVS Shares Newly Purchased by Miller Howard Investments Inc. NY

Miller Howard Investments Inc. NY acquired a new stake in shares of Novartis AG (NYSE:NVS) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 229,623 shares of the company’s stock, valued at approximately $32,737,000.

Several other institutional investors have also recently modified their holdings of NVS. Bank of America Corp DE lifted its position in Novartis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after buying an additional 413,778 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Novartis by 0.8% in the second quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company’s stock worth $365,308,000 after buying an additional 19,595 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Novartis by 1.9% in the first quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock worth $347,649,000 after buying an additional 41,520 shares in the last quarter. WCM Investment Management LLC bought a new position in Novartis during the first quarter valued at approximately $220,004,000. Finally, Sei Investments Co. grew its position in Novartis by 9.6% during the first quarter. Sei Investments Co. now owns 619,274 shares of the company’s stock valued at $94,594,000 after acquiring an additional 54,262 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Price Performance

Shares of Novartis stock opened at $153.93 on Tuesday. The firm has a market cap of $293.72 billion, a PE ratio of 23.22, a price-to-earnings-growth ratio of 2.74 and a beta of 0.41. Novartis AG has a 12-month low of $121.57 and a 12-month high of $170.46. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The company’s fifty day simple moving average is $148.13 and its two-hundred day simple moving average is $151.40.

Analyst Ratings Changes

Several research firms have commented on NVS. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research note on Thursday. Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of Novartis in a report on Thursday, September 17th. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, July 23rd. Morgan Stanley reaffirmed an “overweight” rating and set a $156.00 target price on shares of Novartis in a report on Tuesday, October 6th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novartis in a research report on Sunday, August 9th. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $145.60.

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.